Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

被引：10
|
作者：
Pan, Kathy [1 ]
Bosserman, Linda Diana [2 ]
Chlebowski, Rowan T. [1 ]
机构：
[1] Los Angeles Biomed Res Inst, 1124 W Carson St,Bldg N-16, Torrance, CA 90502 USA
[2] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 11期
关键词：
WOMEN; TAMOXIFEN; EFFICACY;
D O I：
10.1200/JCO.18.01360
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：858 / +
页数：5
相关论文
共 50 条
  • [41] Ovarian Suppression in the Management of Premenopausal Breast Cancer: Methods and Efficacy in Adjuvant and Metastatic Settings
    Wade, Seaborn McDonald, III
    Hackney, Mary Helen
    Khatcheressian, James
    Lyckholm, Laurie J.
    [J]. ONCOLOGY, 2008, 75 (3-4) : 192 - 202
  • [42] Depression and anxiety after adjuvant ovarian function suppression in premenopausal breast cancer patients
    Yi, H. W.
    Nam, S. J.
    Kim, S. W.
    Lee, J. E.
    Lee, S. K.
    Bae, S. Y.
    Park, S.
    Paik, H-J
    Ryu, J. M.
    [J]. CANCER RESEARCH, 2016, 76
  • [43] Evaluation of Adjuvant! Online to predict the effect of optimal endocrine therapy (ovarian function suppression plus tamoxifen) for premenopausal breast cancer patients with estrogen-receptor-positive breast cancer
    Paridaens, R. J.
    Gelber, S.
    Cole, B. F.
    Gelber, R. D.
    Thuerlimann, B.
    Price, K.
    Holmberg, S.
    Crivellari, D.
    Coates, A. S.
    Goldhirsch, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [44] Role of ovarian ablation for premenopausal patients in adjuvant systemic therapy of breast cancer
    Harder, H
    [J]. TROPICAL DOCTOR, 1996, 26 (02) : 85 - 85
  • [45] Re: Ovarian ablation or suppression in premenopausal early breast cancer: Results from the International Adjuvant Breast Cancer ovarian Ablation or Suppression Randomized Trial
    Ferretti, Gianluigi
    Felici, Alessandra
    Carlini, Paolo
    Cognetti, Francesco
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (17) : 1344 - 1345
  • [46] Use of ovarian suppression with endocrine therapy among premenopausal United States women with breast cancer, 2001-2016.
    Mayer, Sophie Emma
    Lund, Jennifer Leigh
    Pate, Virginia
    Reeder-Hayes, Katherine Elizabeth
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Use of ovarian suppression with endocrine therapy among premenopausal women with breast cancer in the United States, 2001-2016
    Mayer, Sophie E.
    Lund, Jennifer L.
    Pate, Virginia
    Reeder-Hayes, Katherine E.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 545 - 546
  • [48] Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy
    Arriagada, R
    Lê, MG
    Spielmann, M
    Mauriac, L
    Bonneterre, J
    Namer, M
    Delozier, T
    Hill, C
    Tursz, T
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (03) : 389 - 396
  • [49] Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update
    Glassman, Daniel
    Hignett, Sue
    Rehman, Shazza
    Linforth, Richard
    Salhab, Mohamed
    [J]. ANTICANCER RESEARCH, 2017, 37 (10) : 5329 - 5341
  • [50] Ovarian ablation by radiotherapy; is it still an option for the ovarian function suppression in endocrine responsive premenopausal breast cancer patients?
    Bese, N. S.
    Iribas, A.
    Oksuz, D. C.
    Atkovar, G.
    Ober, A.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 341S - 341S
12345